Trial Profile
Phase IV, single arm study to obtain information regarding the safety and efficacy of fondaparinux given outpatient for treatment of acute pulmonary embolism
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase IV
Latest Information Update: 29 Jun 2023
Price :
$35
*
At a glance
- Drugs Fondaparinux sodium (Primary) ; Warfarin
- Indications Pulmonary embolism
- Focus Therapeutic Use
- 26 Jan 2017 Status changed to withdrawn prior to enrolment as enrollment criteria not met by PI patient population
- 08 May 2007 New trial record.